Deciphera Pharmaceuticals Inc.

18/07/2024 | Press release | Distributed by Public on 19/07/2024 08:15

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.